ALX2004 vs Becotatug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

ALX2004

Developed by ALX Oncology Inc.

Phase 1 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07085091 (registry estimate)

No aligned efficacy figure on record for this race.

Becotatug

Developed by Shanghai JMT-Bio

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT06380348 · Phase 3 · not yet recruiting

This was a randomized, open-label Phase 3 trial with 398 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-24. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.

Next expected readout: March 2027 · NCT06380348 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) as assessed by Independent Review Center (IRC) per RECIST 1.1 (Up to approximately 35 months after the first participant is randomized): Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24). (met)

Result source: NCT06380348

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALX2004Becotatug
PFS, median—Not reported—Trial running · NCT06319313
OS, median—Not reported—Trial running · NCT06319313
ORR—Not reported—Trial running · NCT06319313
Duration of response, median—Not reported—Trial running · NCT06319313

PFS, median

ALX2004
—Not reported
Becotatug
—Trial running · NCT06319313

OS, median

ALX2004
—Not reported
Becotatug
—Trial running · NCT06319313

ORR

ALX2004
—Not reported
Becotatug
—Trial running · NCT06319313

Duration of response, median

ALX2004
—Not reported
Becotatug
—Trial running · NCT06319313
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALX2004: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Becotatug
Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24). NCT06380348 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · Becotatug's landscape